Sirnaomics Closes $47 Million Series C Financing to Develop RNAi Therapeutics for Treatment of Cancer and Fibrotic Diseases GAITHERSBURG, Md., April 26, 2019-- Sirnaomics Inc., a leading biopharmaceutical company in discovery and development of RNAi therapeutics against cancer and fibrotic diseases, announced today that it has sealed the C2 round of financing for $22 million. This round of funding was led by CR-CP Life Sciences Fund, a Hong Kong based joint venture established by China Resources Group and Charoen Pokphand Group, two Asian conglomerates.